New research reveals that patients who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight far faster than those who halt traditional lifestyle regimens.
Research printed in a prominent medical journal points out that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these drugs should be informed of the danger of fast weight regain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a return to pre-treatment weight within about 18 months.
Analyzing Therapies
The research, which looked at 37 of trials involving over 9,000 of patients, compared the results of these new drugs with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone typically see a slower weight regain—around 100 grams monthly—post-intervention.
Explaining the Quick Regain
Experts suggest the mechanism of the drugs explains the heightened regain.
The injections imitate a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of the hormone concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating far more likely."
A Chronic Issue?
The NHS advise the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts contend that, due to the high risk of relapse, the therapy might need to be long-term.
This opinion is echoed by pharmaceutical companies, who state that the results "underscore the persistent nature of obesity," similar to managing diseases like diabetes.
User Experiences
People who have discontinued the jabs report a intense return of appetite.
"I experienced a switch that goes on and you're instantly ravenous," described a patient.
This difficulty is compounded if patients have not adopted lasting lifestyle or habit modifications during therapy.
Significant Interest
Recent estimates show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and maintained weight loss relies on integrated behavioural support.
